An anti-TIGIT antibody that engages with the immune system in multiple ways.
At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
The ATP-adenosine pathway is recognized as a key pathway that modulates immune responses in pathological conditions. We designed Inupadenant to inhibit the ATP-adenosine pathway by specifically targeting A2AR, which is the primary adenosine receptor on immune cells with a high affinity for adenosine.
Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.
Latest press releases
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company…
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
– Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a…